Generate BiomedicinesGENB +2.18%6 FCF Yield % is -9.42 as of Jun. 29, 2026. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,415 Biotechnology companies, Generate Biomedicines ranks worse than 50.04% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Generate Biomedicines FCF Yield % Related Terms
Generate Biomedicines FCF Yield % Historical Data
* Premium members only.
The historical data trend for Generate Biomedicines's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generate Biomedicines FCF Yield % Chart
Generate Biomedicines Annual Data
Trend
Dec24
Dec25
FCF Yield %
0.00
0.00
Generate Biomedicines Semi-Annual Data
Dec24
Dec25
FCF Yield %
0.00
0.00
GENB vs PVLA, SLBT, NKTR: FCF Yield % Comparison
For the Biotechnology subindustry, Generate Biomedicines's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Generate Biomedicines FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Generate Biomedicines's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Generate Biomedicines's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generate Biomedicines (GENB) has a FCF Yield % of -9.42 as of Jun. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Generate Biomedicines and its competitors. According to the industry distribution chart, Generate Biomedicines ranks #708 out of 1415 companies in the Biotechnology industry, placing it in the top 50%.
Is Generate Biomedicines' FCF Yield % too high?
Generate Biomedicines' current FCF Yield % is -9.42. Based on the distribution chart, Generate Biomedicines ranks #708 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' FCF Yield % compare to PVLA and SLBT?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #708 out of 1415 companies for FCF Yield %. This puts Generate Biomedicines in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current FCF Yield % is -9.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current FCF Yield % of -9.42. The current FCF Yield % is -9.42. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current FCF Yield % is -9.42 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score
Get the complete analysis for GENB
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENB has been successfully added to your 